"Lung EpiCheck’s simplicity and performance are needed in the current landscape of early detection of lung cancer. I believe that it could serve as an excellent population-wide approach to identify subjects at risk of having lung cancer".
Early stage lung cancer detection for those at high risk
THE NEED
Lung cancer remains a leading cause of death from cancer globally, due to its high incidence and late-stage diagnosis. Most patients are currently diagnosed with late-stage cancer, though research has shown 5-year survival rates are up to 10 times greater when disease is detected early. Annual imaging (low-dose CT scans) is recommended for screening individuals with highest risk, but less than 10% of those eligible adhere to guidelines2. Delivering an effective screening option for high risk individuals could increase compliance for imaging and drive more patients to treatment when it can have the greatest chance of having a long-term benefit.
OUR SOLUTION
Lung EpiCheck® will be a simple, blood-based test that will detect lung tumor DNA circulating in human blood. The test is intended to detect subtle disease-specific changes in DNA methylation markers.
Prof. Mina Gaga
Athens Chest Hospital, Greece